Royalty Report: Drugs, Cancer, Diagnostic – Collection: 27384

$100.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 3

Primary Industries

  • Drugs
  • Cancer
  • Diagnostic
  • Biotechnology
  • Disease

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 27384

License Grant
The Licensor is providing the Company with an exclusive worldwide license to certain of the Licensor’s existing human genome technologies that are useful for purposes of development and commercialization of certain of the Company’s services, including: (i) testing, detection and/or analysis of cancer-predisposing genes; (ii) genetic assessment of risk of an individual to develop cancer; and (iii) testing and analysis for the purposes of cancer management.
License Property
In addition, the Licensor is providing the Company with a non-exclusive worldwide license to certain of the Licensor’s existing human genome technologies, and any future improvements thereto, to be used by the Company in the provision of services direct to third parties other than those to whom services are provided pursuant to the exclusive license.
Field of Use
The rights granted apply for the purposes of cancer management in the Medical Field using human genome technologies.

IPSCIO Record ID: 2305

License Grant
Licensor is providing the Company with an exclusive worldwide license to Licensor’s existing and future human genome technologies that are useful for the purposes of development and commercialization of certain of the Company's services, including: (i) testing, detection and/or analysis of cancer-predisposing genes; (ii) genetic assessment of risk of an individual to develop cancer; and (iii) testing and analysis for the purposes of cancer management.
License Property
The proprietary technologies include functional gene assay and microsatellite instability technology.  In addition, the Company currently uses conventional gene sequencing to detect gene mutations.  The Company intends to utilize protein truncation methods, Oncor’s proprietary Tri-Amp DNA amplification technology, various gel electrophoresis screening methods and automation to detect genetic mutations.
Field of Use
The Licensee was formed to develop genetic testing and information services for the early detection and management of cancer.  Also engaged in research and development programs and organizational efforts.  The rights granted apply to the healthcare industry.

IPSCIO Record ID: 26399

License Grant
The Company has entered into various license agreements with undisclosed licensors pursuant to which it has been granted use of certain patented technologies related to: the developing field of genomics, a direct offshoot of the Human Genome Project that seeks to identify and understand the genetic basis of disease; the evaluation and management of cancer, prenatal disorders and other genetic diseases.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.